include preclinical development, clinical evaluation of Treg-based therapies, and collaboration frameworks for advancing new modalities in immune-mediated conditions. Sonoma Biotherapeutics engages with partners and stakeholders across research, manufacturing, and clinical operations to bring engineered cell therapies from concept toward clinical proof of concept.